ArticleBiotechnology journal2017
Predictive glycoengineering of biosimilars using a Markov chain glycosylation model.
Article in Biotechnology journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Glycoengineered Recombinant Alpha1-Antitrypsin Results in Comparable In Vitro and In Vivo Activities to Human Plasma-Derived Protein.Biotechnology and bioengineering · 2026Article
- Advances in Biosimilars: A Systematic Review of Machine Learning Applications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Glycoengineering of the hepatitis C virus E2 glycoprotein improves biochemical properties and enhances immunogenicity.NPJ vaccines · 2025Article
- Glycoengineering of the hepatitis C virus E2 glycoprotein leads to improved biochemical properties and enhanced immunogenicity.bioRxiv : the preprint server for biology · 2025Article
- Boltzmann Model Predicts Glycan Structures from Lectin Binding.Analytical chemistry · 2024Article
- A Boltzmann model predicts glycan structures from lectin binding.bioRxiv : the preprint server for biology · 2024Article
- LipidSIM: Inferring mechanistic lipid biosynthesis perturbations from lipidomics with a flexible, low-parameter, Markov modeling framework.Metabolic engineering · 2024Article
- Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies.Biotechnology advances · 2023Review
- A roadmap for translational cancer glycoimmunology at single cell resolution.Journal of experimental & clinical cancer research : CR · 2022Review
- Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy.Journal of biomedical science · 2021Review
- Big-Data Glycomics: Tools to Connect Glycan Biosynthesis to Extracellular Communication.Trends in biochemical sciences · 2021Review
- A Markov model of glycosylation elucidates isozyme specificity and glycosyltransferase interactions for glycoengineering.Current research in biotechnology · 2020Article
- A consensus-based and readable extension ofBeilstein journal of organic chemistry · 2020Article
- Protein Glycoengineering: An Approach for Improving Protein Properties.Frontiers in chemistry · 2020Review
- Proteogenomic Annotation of Chinese Hamsters Reveals Extensive Novel Translation Events and Endogenous Retroviral Elements.Journal of proteome research · 2019Article
- Quantum Modeling: A Bridge between the Pumping and Signaling Functions of Na/K-ATPase.International journal of molecular sciences · 2018Article
- The emerging role of systems biology for engineering protein production in CHO cells.Current opinion in biotechnology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Biosimilar drugs must closely resemble the pharmacological attributes of innovator products to ensure safety and efficacy to obtain regulatory approval. Glycosylation is one critical quality attribute that must be matched, but it is inherently difficult to control due to the complexity of its biogenesis. This usually implies that costly and time-consuming experimentation is required for clone identification and optimization of biosimilar glycosylation. Here, a computational method that utilizes a Markov model of glycosylation to predict optimal glycoengineering strategies to obtain a specific glycosylation profile with desired properties is described. The approach uses a genetic algorithm to find the required quantities to perturb glycosylation reaction rates that lead to the best possible match with a given glycosylation profile. Furthermore, the approach can be used to identify cell lines and clones that will require minimal intervention while achieving a glycoprofile that is most similar to the desired profile. Thus, this approach can facilitate biosimilar design by providing computational glycoengineering guidelines that can be generated with a minimal time and cost.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.